A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether the radial artery provides better long-term patency than the saphenous vein. Altogether 379 papers were found using the reported search, of which 12 presented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We concluded that there is evidence that radial artery grafts have a higher rate of patency than saphenous vein grafts. Surgeons can confidently use the radial artery as a second arterial bypass graft, particularly in patients with severe native-vessel stenosis.
Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in the ICVTS w1x.
Clinical scenario
You are about to perform a coronary artery bypass graft (CABG) on an obese 65-year-old man who has triple-vessel disease involving the left anterior descending (LAD) artery, the first obtuse marginal (OM) branch, and the posterior descending artery (PDA), and an akinetic inferior wall with an estimated ejection fraction of 40%. You wonder whether you should use the saphenous vein (SV) or the radial artery (RA) to graft a heavily diseased PDA or OM to achieve longterm patency.
Three part question
In patients undergoing wcoronary artery bypass graftingx is the wradial artery or saphenous veinx the better conduit to achieve wlong-term patencyx.
Search strategy
Medline 1966-Feb 2005 using OVID interface. wexp Cardiac Surgical ProceduresyOR exp Coronary Artery BypassyOR exp Myocardial RevascularizationyOR exp Cardiovascular Surgi-*Corresponding author. Tel.: q972-3-937-6701; fax: q972-3-924-0762. E-mail address: georgios@clalit.org.il (G.P. Georghiou).
cal ProceduresyOR exp Cardiopulmonary BypassyOR Coronary art$ bypass.mp OR CABG.mp OR Cardiac surg$.mpx AND (exp radial arteryyOR radial arter$.mpx AND wexp veinsyOR vein.mpx
Search outcome
Three hundred and seventy-seven papers were found of which 9 were deemed relevant. Cross-checking of the reference lists revealed another three papers w2-13x. The 12 papers are presented in Table 1 .
Comments
Several angiographic observational studies have shown that the RA has excellent short-, mid-, and long-term patency when used as a conduit for revascularization w2-10,12,13x (Table 1) . However, Khot et al. w11x reported a high rate of both occlusion and severe flow-limiting disease with the use of RA grafts in patients presenting predominantly with recurrent signs or symptoms of myocardial ischemia after CABG. The RA graft results were dramatically inferior to those for internal mammary artery (IMA) bypass grafts and SV grafts. Although angiographic outcomes with the RA graft were poorer in both sexes, women had particularly high rates of occlusion. It should be noted, though, that this study had a number of limitations. The results were confounded by a selection bias, because the sample was limited to patients with symptoms or signs of recurrent ischemia. Thus, the low RA graft patency rate may have been attributable to the high-risk status of the population rather than an intrinsic tendency of the graft itself. Furthermore, previous studies restricted RA graft placement to patients with high-grade stenosis and good distal runoff, whereas in this study, the decision to use a RA graft was made at the discretion of the individual surgeon, thereby mimicking 'real-life' use. As such, the results may have reflected the less stringent criteria for RA bypass.
Recently, Zacharias et al. w13x evaluated the 6-year outcome of propensity-matched patients undergoing left IMA (LIMA)-to-LAD grafting with one or more additional RA grafts or vein-only grafts (ns925 each). Perioperative outcomes, including death rate, were similar in the two groups, although cumulative survival was better in the patients with the RA graft(s). Angiographic data in restudied symptomatic patients showed a trend for greater RA graft patency. In patients who received both types of grafts, the extent of failure was significantly worse in the vein graft than the RA graft. These findings favor the use of the RA as a second arterial conduit in LIMA-LAD CABG. Possati et al. w9x , in a series of 90 consecutive patients with CABG, reported an 88% long-term (mean 105"9 months) angiographic patency of RA grafts anastomosed to an OM or PDA. This rate was lower than for LIMA grafts (96.3%) but significantly higher than for SV grafts (53.4%), supporting the use of the RA as a complementary conduit for myocardial revascularization. Although these results are encouraging, there are few additional long-term randomized, controlled studies on RA graft patency in symptom-free patients.
To bridge this gap, the prospective single-center Radial Artery Patency and Clinical Outcome (RAPCO) Study w8x is conducting a 10-year comparison of angiographic patency and cardiac outcome between RA grafts and either free right IMA (RIMA) grafts (ns25, age -70 years) or SV grafts (ns153, age G75 years) branched to the largest available coronary artery other than the LAD. Interim analysis at 5 years showed no differences in angiographic failure rates or major clinical outcomes (namely, survival and cardiac event-free survival) between the groups. However, these findings were based on only a small proportion of the expected angiographic results. Furthermore, the SV graft patency rates were much higher than rates in both previous reports and in the non-study SVs, perhaps because in SV grafts, atherosclerosis and dysfunction begin to increase only 5 to 10 years postoperatively. The final results at 10 years should help to clarify whether RA grafts are superior to RIMA and SV grafts in this setting.
The interim results of a second prospective multicenter trial, the Radial Artery Patency Study (RAPS) w11x, were published in 2004. The investigators compared the 8-to 12-month protocol-directed angiographic patency of RA and SV grafts to the right or circumflex coronary arteries in 561 patients. Each patient served as hisyher own control. Significantly higher patency rates were noted in the RA graft group (91.8% vs. 86.4%; Ps0.01; graft occlusion odds ratios0.53; 95% confidence interval 0.31-0.85); rates of perfect graft patency (i.e., TIMI 3 flow) were similar (87.7% vs. 85.7%, Ps0.37). In the RA group, graft patency was similar in the inferior (right coronary) and lateral (circumflex) territories, and perfect patency was highly dependent on the severity of the proximal native coronary artery stenosis (70-89% coronary stenosis: 81.7% patency, G90% stenosis: 91.5% patency). The long-term (5 to 10 years) findings will be assessed in follow-up studies.
In summary, RA patency rates exceeded those of SV grafts at all time points, except in one study w5x. The tabulated studies show a 10-year patency of 50-90% for RA grafts and of 30-50% for SV grafts.
Clinical bottom line
The RA graft has a significantly better long-term patency than the SV graft. Although these findings are encouraging, the final results of the RAPCO and RAPS trials after 10 years of follow-up in symptom-free patients should help to clarify the long-term patency rates of RA grafts and to determine whether RA grafts yield better results than SV grafts.
